Disrupting Modern Healthcare

    The Psychedelics as Medicine Report: Third Edition

    The Psychedelics as Medicine Report: Third Edition provides unparalleled consumer insights and market intelligence from experts and industry leaders, helping investors cut through the noise and identify real opportunities.

    The Psychedelics as Medicine Report: Third Edition examines

    • Proprietary insights from consumers and healthcare providers
    • Deep dives into the most transformative compounds and companies
    • Key regulations, transformative trends and commercial opportunities

    Table of Contents

    • Introduction
    • Definition and Scope
    • Executive Summary
    • Key Trends
    • Market Value
    • Legislation and Regulation
    • Consumer Attitudes
    • Healthcare Providers’ Attitudes
    • Spotlight on Health
    • Psychedelics - Timeline of Key Developments
    • Countries to Watch
    • Psychedelic Profiles
    • Key Psychedelics of Note
    • Psychedelics As Medicines - Potential Therapies
    • Psychedelics and Technology
    • Psychedelics per Country
    • Psychedelics and the Law
    • Patents and Intellectual Property
    • Therapists and Doctors
    • Psychedelic Research
    • Glossary

    Key Trends

    • Research is at a tipping point
    • Psychedelics poised to treat many disorders
    • Therapy will be the name of the game
    • Legislation and regulation moving in the right direction
    • Patients and doctors are ready for change

    Market Value

    • Approval landscape
    • Projected growth of medical psychedelics market
    • The cost of illness
    • Economic health model
    • Mental health during the COVID-19 pandemic

    Consumer Attitudes

    • Consumer’s take on psychedelics as medicine
    • The education opportunity
    • Psychedelics of choice
    • Influence of prior drug use on openness to psychedelic-assisted therapies

    Healthcare Provider Attitudes

    • State of mental health: Healthcare workers
    • Psychedelic expertise of healthcare workers
    • Healthcare workers' familiarity with psychedelic-assisted therapy
    • Therapy: The benefits and challenges
    • Healthcare workers’ attitudes towards the medical benefits of psychedelics
    • Influence of psychedelic use on practitioner views

    Spotlight on Health

    • Psychedelics coming out the closet
    • Novel ways of treating persistant problems
    • Total number of clinical trials
    • Key conditions
    • Percentage of mental health and substance use disorders
    • Facts about mental health conditions
    • Psychedelic history and future
    • Why Psychedelics are different

    Key Psychedelic Deep Dives

    • Psilocybin
    • LSD
    • MDMA
    • Ketamine
    • Ibogaine
    • Ayahuasca

    Other Psychedelics of Note

    • Salvia Divinorum
    • Mescaline
    • DMT
    • 5-MeO-DMT
    • Kratom
    • 2C-X
    • Nitrous Oxide

    Psychedelics per Country

    • Australia
    • Brazil
    • Canada
    • China
    • Denmark
    • Germany
    • Ireland
    • Netherlands
    • Spain
    • Switzerland
    • United Kingdom
    • United States

    Expert Contributors

    • Florian Brand – Co-founder and CEO, atai Life Sciences
    • George Goldsmith – Co-founder and CEO, COMPASS Pathways
    • Cosmo Feilding Mellen – CEO, Beckley Psytech
    • Dr Roger McIntyre – CEO, Braxia Scientific
    • Dr Reid Robison – Chief Medical Officer and Director, Novamind
    Download report

    In collaboration with